Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Beryl Drugs Ltd held its 4th Board Meeting of FY 2025-26 on 13th November 2025 at its registered office in Indore. The Board considered and approved the Unaudited Financial Results for the quarter ended 30th September 2025 (Q2 FY26). The Board also noted the Limited Review Report submitted by the statutory auditors on these quarterly results. No specific financial figures, dividend declarations, or other significant decisions were disclosed in this filing.
This is a routine regulatory filing confirming timely approval of quarterly results and auditor review. There is no immediate material impact on shareholders as no major corporate actions like fundraising, acquisitions, or dividend changes were announced.